Nasdaq · CIK 0000109657
GTBP GT Biopharma, Inc.
Insider trading from SEC Form 4. Last filing Sep 8, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
5
with a Form 4 at this company
Signals
Open-market buys and sells at GT Biopharma, Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 9 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 4, 2025 | Michael Martin Breen CEO and Director | AGrant or award Option to purchase Common Stockderivative | +100,000 | $0.00 | $0 | 100,000 | Sep 8, 2025 |
| Sep 4, 2025 | Charles J Casamento director | AGrant or award Option to purchase Common Stockderivative | +62,500 | $0.00 | $0 | 62,500 | Sep 8, 2025 |
| Sep 4, 2025 | Hilary Kramer director | AGrant or award Option to purchase Common Stockderivative | +31,250 | $0.00 | $0 | 31,250 | Sep 8, 2025 |
| Sep 4, 2025 | David C. Mun-Gavin director | AGrant or award Option to purchase Common Stockderivative | +31,250 | $0.00 | $0 | 31,250 | Sep 8, 2025 |
| Sep 4, 2025 | Alan Louis Urban Chief Financial Officer | AGrant or award Option to purchase Common Stockderivative | +50,000 | $0.00 | $0 | 50,000 | Sep 8, 2025 |
| Sep 4, 2025 | Michael Martin Breen CEO and Director | AGrant or award Option to purchase Common Stockderivative | +100,000 | $0.00 | $0 | 100,000 | Sep 8, 2025 |
| Sep 4, 2025 | Alan Louis Urban Chief Financial Officer | AGrant or award Option to purchase Common Stockderivative | +50,000 | $0.00 | $0 | 50,000 | Sep 8, 2025 |
| Sep 4, 2025 | Michael Martin Breen CEO and Director | AGrant or award Option to purchase Common Stockderivative | +100,000 | $0.00 | $0 | 100,000 | Sep 8, 2025 |
| Oct 17, 2024 | Alan Louis Urban Chief Financial Officer | AGrant or award Option to purchase Common Stockderivative | +23,335 | $0.00 | $0 | 23,335 | Oct 21, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Michael Martin BreenCEO and Director
- Charles J Casamentodirector
- Hilary Kramerdirector
- David C. Mun-Gavindirector
- Alan Louis UrbanChief Financial Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.